Enterome to Participate in the Jefferies Global Healthcare Conference
30 May 2024
Phase 2Immunotherapy
Enterome to Participate in the Jefferies Global Healthcare Conference
PARIS, May 30, 2024 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announces that Pierre Bélichard, Enterome’s co-founder and Chief Executive Officer, and Christelle Dumoussaud, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY on June 4-6, 2024.
About Enterome
Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases. Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, which allows it to analyze and uncover new biological insights from the millions of gut bacterial proteins in constant cross-talk with the human body.
Enterome’s first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect, or actions of specific antigens, hormones, or cytokines.
The company is currently developing a pipeline of drug candidates consisting of:
OncoMimics™ peptide-based immunotherapies for the treatment of cancer, including EO2463 and EO2401. EO2463 is in a Phase 2 clinical trial for indolent non-Hodgkin lymphomas, demonstrating a benign safety profile with encouraging early signs of efficacy. EO2401 has successfully completed a Phase 2 clinical trial in patients with glioblastoma, and Enterome is currently seeking a pharmaceutical partner to further develop a pivotal trial.
EndoMimics™ peptides, a pipeline of next-generation bioactive therapeutic proteins acting like human hormones or cytokines, being developed in collaboration with Nestlé Health Science for food allergies and inflammatory bowel disease (IBD).
Enterome employs 70 people and is headquartered in Paris, France. Since its inception, the company has raised a total of €118 million from Europe- and US-based life science investors and more than €100 million from pharmaceutical partnerships.
Contacts
ENTEROMEMEDIA RELATIONSGuillaume Bayre
Head of External Communications
Tel: +33 (0)1 76 21 58 15
communication@enterome.comLifeSci Advisors LLC
Ashley R. Robinson (US)
+1 617 430 7577
arr@lifesciadvisors.com
Sandya von der Weid (Europe)
+41 78 680 05 38
svonderweid@lifesciadvisors.com
For more information, please visit the company’s website at: www.enterome.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.